EGI
APLS

EAM Global Investors’s Apellis Pharmaceuticals APLS Stock Holding History

EAM Global Investors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-27,245
Closed -$1.86M – 179
2022
Q3 		$1.86M Buy
+27,245
New +$1.61M 0.49% 85

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EAM Global Investors's APLS Position: Q4 2022 in Review

EAM Global Investors sold out of Apellis Pharmaceuticals (APLS) in Q4 2022, closing a stake of 27,245 shares — an estimated $1.86M sold.

EAM Global Investors first reported a position in APLS in Q3 2022 and held it in 1 quarter. The position peaked at $1.86M in Q3 2022. 244 funds tracked by Wall St. Rank hold APLS as of Q4 2022.

  • EAM Global Investors reported no remaining Apellis Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • EAM Global Investors sold 27,245 Apellis Pharmaceuticals shares in Q4 2022, an estimated $1.86M.
  • EAM Global Investors first reported a position in Apellis Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • EAM Global Investors's Apellis Pharmaceuticals position peaked at $1.86M in Q3 2022.
  • 244 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2022.

Based on EAM Global Investors's 13F filing for Q4 2022, filed 14 Feb 2023.